Affiliation:
1. Department of Orthopaedic Surgery, Fukushima Medical University, Fukushima, Japan
2. Eli Lilly Turkey, Istanbul, Turkey
3. Shionogi & Co., Ltd., Osaka, Japan
4. Eli Lilly Japan K.K., Kobe, Japan
Abstract
Abstract
Objective
To evaluate the safety and efficacy of duloxetine treatment for 52 weeks.
Design
Multicenter, open-label, phase III clinical study.
Setting
Forty-one medical institutions in Japan.
Subjects
Japanese patients with chronic low back pain (CLBP).
Methods
Duloxetine 60 mg once-daily was administered for 52 weeks. Safety was evaluated based on adverse events (AEs), vital signs, laboratory test values, electrocardiogram, Columbia-Suicide Severity Rating Scale, and occurrence of falls. The efficacy outcome measures were the Brief Pain Inventory (BPI; average pain, worst pain, least pain, and pain right now), BPI Interference, Patient’s Global Impression of Improvement (PGI-I), Clinical Global Impressions of Severity (CGI-S), Roland-Morris Disability Questionnaire–24 (RDQ-24), 36-Item Short-Form Health Survey (SF-36), and European Quality of Life-5 Dimensions Questionnaire (EQ-5D).
Results
In total, 151 patients (83 who completed a 14-week placebo-controlled superiority trial and 68 newly registered patients) were enrolled. The incidence rates of AEs and adverse drug reactions (ADRs) were 86.1% and 50.3%, respectively. ADRs with an incidence of ≥5% were somnolence, constipation, nausea, and dry mouth. Treatment discontinuation for AEs occurred in 16 patients. A significant reduction in the BPI average pain score (mean ± SD) was observed at all assessment time points from week 2 (−1.02 ± 1.37) to week 50 (−2.26 ± 1.63), compared with baseline. BPI pain severity (worst pain, least pain, and pain right now), BPI Interference, PGI-I, CGI-S, RDQ-24, SF-36, and EQ-5D showed significant improvement.
Conclusion
Japanese patients with CLBP had significant pain reduction over 52 weeks without new safety concerns.
Publisher
Oxford University Press (OUP)
Subject
Anesthesiology and Pain Medicine,Neurology (clinical),General Medicine
Reference38 articles.
1. Prevalence of low back pain and factors associated with chronic disabling back pain in Japan;Fujii;Eur Spine J,2013
2. Epidemiology of low back pain – from a large scale epidemiologic survey “ROAD.”;Yoshimura;Nippon Seikei Geka Gakkai Zasshi,2010
3. The association between lower back pain and health status, work productivity, and health care resource use in Japan;Sadosky;J Pain Res,2015
4. Prevalence and characteristics of chronic musculoskeletal pain in Japan: A second survey of people with or without chronic pain;Nakamura;J Orthop Sci,2014
5. Chapter 4. European guidelines for the management of chronic nonspecific low back pain;Airaksinen;Eur Spine J,2006